Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer#Johnson #amp #Johnson039s #TAR200 #monotherapy #demonstrates #highest #complete #response #rate #sustained #clinical #benefits #patients #types #bladder #cancer